# Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

> **NCT00408603** · PHASE2 · COMPLETED · sponsor: **Sunesis Pharmaceuticals** · enrollment: 183 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Voreloxin Injection

## Key facts

- **NCT ID:** NCT00408603
- **Lead sponsor:** Sunesis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-20
- **Primary completion:** 2010-06-09
- **Final completion:** 2010-06-09
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408603, "Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00408603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*